Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by spesestsemperon Jul 03, 2024 4:40pm
138 Views
Post# 36117063

RE:Cause For Concern?

RE:Cause For Concern?I dont think there is cause for concern yet . They just had their fda meeting squared away ,  hired a vp of business development ( still troubles me that there was no nr on this - heck , he isnt even on the website yet ) , started the new pan trial . Lots of positives . The problem with this company is that they have lots of baggage , I'll bet there is alot of people waiting to jump in but they won't do to past unmet promises - they are going to want to see something really solid . In my mind there is a really good chance for some money to be made here. That will change if they dont announce a proper partnership soon . I dont think a buyout is in the cards . I would prefer one but i think they are taking another road . I'm here for a couple more weeks before i sell and move on or the announcement for around $6 pop .Just some idle ramblings on how i see things .
<< Previous
Bullboard Posts
Next >>